A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 20, 2025

Study Completion Date

December 30, 2025

Conditions
Iodine-resistant Thyroid CancerMeningiomaNETs
Interventions
DRUG

68Ga-TATE-RGD

Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.

DRUG

18-FDG

Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.

Trial Locations (1)

010100

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER